NCT00278395View on ClinicalTrials.gov

Vorinostat in Treating Patients With Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Recurrent Renal Cell CarcinomaStage IV Renal Cell Cancer
Interventions
DRUG

Vorinostat

Given orally

Trial Locations (2)

78229

Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio

78245

Institute for Drug Development, San Antonio

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00278395 - Vorinostat in Treating Patients With Kidney Cancer | Biotech Hunter | Biotech Hunter